Overview

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This study will determine whether quarterly injections of Ranibizumab may prevent eyes with dry age-related macular degeneration from progressing to wet age-related macular degeneration (AMD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Southern California Desert Retina Consultants, MC
Treatments:
Ranibizumab